[1]赵爱华, 卢锦标, 王国治. 我国结核病新疫苗研究策略的探讨. 中华微生物学和免疫学杂志, 2013, 33(12): 885-892.[2]Stop TB Partnership Working Group on New TB Vaccine. Tuberculosis vaccine candidates 2010. Geneva: World Health Organization,2010. http://www.stoptb.org/.[3]达泽蛟, 胡丽娜, 王秉翔, 等. 二甲基三十六烷基铵及卡介苗多糖核酸佐剂在结核亚单位疫苗加强BCG免疫中的效应研究. 中华微生物学和免疫学杂志, 2010, 30(6): 555-559.[4]赵爱华, 李凤祥, 寇丽杰, 等. 卡介菌CpG DNA复合佐剂-02系统(BC-C02)有效性与安全性评价. 中国防痨杂志, 2013, 34(3): 161-167.[5]O’Hagan DT, Ott GS, De Gregorio E,et al. The mechanism of action of MF59 an innately attractive adjuvant formulation. Vaccine, 2012, 30(29):4341-4348.[6]Tsai TF. Fluad-MF59-adjuvanted influenza vaccine in older adults. Infect Chemother, 2013, 45(2):159-174.[7]Ott G, Barchfeld GL, Chernoff D,et al. MF59, design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol, 1995, 6:277-296.[8]Vono M, Taccone M, Caccin P,et al. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci U S A, 2013, 110(52):21095-21100.[9]Seubert A, Monaci E, Pizza M,et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol, 2008, 180(8):5402-5412.[10]O′Hagan DT, Ott GS, Nest GV, et al. The history of MF59 adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines, 2013, 12(1):13-30.[11]Parkash O. Vaccine against tuberculosis: a view. J Med Microbiol,2014.[12]Haile M, Schroder U, Hamasur B,et al. Immunization with heat-killed Mycobacterium bovis bacilli Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine, 2004, 22(11/12):1498-1508.[13]Kakeda M, Yamanaka K, Kitagawa H,et al. Heat-killed bacillus Calmette-Guérin and Mycobacterium kansasii antigen 85B combined vaccination ameliorates dermatitis in a mouse model of atopic dermatitis by inducing regulatory T cells. Br J Dermatol, 2012, 166(5):953-963.[14]Dey AK, Burke B, Sun Y,et al. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. Vaccine,2012,30(17):2749-2759.[15]Griffiths PD, Stanton A, McCarrell E,et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant reci-pients: a phase 2 randomised placebo-controlled trial. Lancet, 2011, 377(9773):1256-1263.[16]Baudner BC, Ronconi V, Casini D,et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res, 2009, 26(6):1477-1485.[17]Burke B, Gómez-Román VR, Lian Y, et al. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology, 2009, 387(1):147-156.[18]Yang M, Yan Y, Fang M,et al. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. Int Immunopharmacol, 2012, 13(4):408-416.[19]李登瑞, 杨永辉, 孙巍. 结核病的先天性免疫与TLR2/4/9的关系. 中国防痨杂志, 2011, 33(3): 173-178.[20]Chee CB, Gan SH, Khinmar KW,et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol, 2008, 46(6):1935-1940.[21]李传友, 邢爱英, 李亮, 等. 结核分支杆菌感染巨噬细胞后氮氧化物的产生及细胞因子表达的研究. 中华结核和呼吸杂志, 2003,26(4):214-217.[22]徐苗, 陈保文, 沈小兵, 等. 耻垢分枝杆菌疫苗对小鼠细胞因子产生及Th1/Th2应答的影响. 中华结核和呼吸杂志, 2005, 28(11):781-784. |